Nova Eye Medical Limited (ELXMF) Shareholder/Analyst Call Transcript

Core Viewpoint - Nova Eye Medical has reported its half-year results for the period ending December 31, 2025, and highlighted the significance of its recent EU MDR certification as a major regulatory milestone that supports its commercial activities in Europe and beyond [1][2] Financial Performance - The Managing Director will present key financial outcomes, including progress in margins and EBITDA, as well as cash flow details for the first half of FY '26 [1] Strategic Importance - Securing the EU MDR certification is emphasized as a critical achievement for the company, facilitating ongoing commercial efforts in Europe and other regions [2]